Matthew D. Hellmann

98.0k total citations · 16 hit papers
231 papers, 21.4k citations indexed

About

Matthew D. Hellmann is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Matthew D. Hellmann has authored 231 papers receiving a total of 21.4k indexed citations (citations by other indexed papers that have themselves been cited), including 204 papers in Oncology, 129 papers in Pulmonary and Respiratory Medicine and 55 papers in Cancer Research. Recurrent topics in Matthew D. Hellmann's work include Cancer Immunotherapy and Biomarkers (158 papers), Lung Cancer Treatments and Mutations (111 papers) and Cancer Genomics and Diagnostics (54 papers). Matthew D. Hellmann is often cited by papers focused on Cancer Immunotherapy and Biomarkers (158 papers), Lung Cancer Treatments and Mutations (111 papers) and Cancer Genomics and Diagnostics (54 papers). Matthew D. Hellmann collaborates with scholars based in United States, Spain and Germany. Matthew D. Hellmann's co-authors include Michael A. Postow, Robert Sidlow, Adam J. Schoenfeld, Mark G. Kris, Jamie E. Chaft, Jedd D. Wolchok, Hira Rizvi, Scott Antonia, Naiyer A. Rizvi and Gregory J. Riely and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Matthew D. Hellmann

227 papers receiving 21.2k citations

Hit Papers

Immune-Related Adverse Events Associated with Immune Chec... 2014 2026 2018 2022 2018 2018 2018 2016 2018 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
    2018 3.2k citations Michael A. Postow, Matthew D. Hellmann et al. profile →
  2. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2018 1.6k citations Matthew D. Hellmann et al. profile →
  3. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
    2018 712 citations Kathryn C. Arbour, Niamh M. Long et al. profile →
  4. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
    2016 700 citations Matthew D. Hellmann, Naiyer A. Rizvi et al. profile →
  5. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
    2018 670 citations Matthew D. Hellmann, Margaret K. Callahan et al. profile →
  6. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
    2018 631 citations Matthew D. Hellmann, Darragh Halpenny et al. profile →
  7. Chromatin states define tumour-specific T cell dysfunction and reprogramming
    2017 605 citations Taha Merghoub, Matthew D. Hellmann et al. profile →
  8. Acquired Resistance to Immune Checkpoint Inhibitors
    2020 600 citations Adam J. Schoenfeld, Matthew D. Hellmann profile →
  9. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
    2018 539 citations Matthew D. Hellmann et al. profile →
  10. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
    2016 486 citations Ai Ni, Jamie E. Chaft et al. profile →
  11. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
    2017 445 citations Vladimir Makarov, Matthew D. Hellmann et al. profile →
  12. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
    2014 416 citations Matthew D. Hellmann, Jamie E. Chaft et al. profile →
  13. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    2016 394 citations Naiyer A. Rizvi, Jonathan W. Goldman et al. profile →
  14. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    2016 350 citations Naiyer A. Rizvi, Matthew D. Hellmann et al. profile →
  15. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
    2016 325 citations Natasha Rekhtman, M. Catherine Pietanza et al. Clinical Cancer Research profile →
  16. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
    2019 271 citations Adam J. Schoenfeld, Kathryn C. Arbour et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew D. Hellmann United States 61 16.4k 9.0k 4.9k 4.1k 2.7k 231 21.4k
Martin Reck Germany 56 17.5k 1.1× 13.7k 1.5× 2.7k 0.5× 4.5k 1.1× 3.2k 1.2× 402 22.9k
Benjamin Besse France 64 12.2k 0.7× 10.4k 1.2× 2.2k 0.5× 5.6k 1.4× 3.8k 1.4× 708 18.8k
Delvys Rodríguez‐Abreu Spain 38 15.1k 0.9× 10.1k 1.1× 3.5k 0.7× 2.0k 0.5× 2.0k 0.7× 186 18.0k
Christina B. Walter Germany 6 18.1k 1.1× 6.3k 0.7× 8.9k 1.8× 6.7k 1.6× 4.5k 1.7× 13 25.0k
Janis M. Taube United States 55 15.5k 0.9× 4.8k 0.5× 7.9k 1.6× 3.6k 0.9× 2.3k 0.8× 205 20.7k
Florin‐Andrei Taran Germany 23 18.6k 1.1× 6.6k 0.7× 8.9k 1.8× 6.8k 1.7× 4.9k 1.8× 77 26.3k
David R. Spigel United States 68 14.4k 0.9× 9.9k 1.1× 1.7k 0.4× 5.0k 1.2× 2.9k 1.1× 611 20.0k
Andreas D. Hartkopf Germany 24 19.3k 1.2× 6.8k 0.8× 9.0k 1.8× 7.1k 1.7× 5.5k 2.0× 169 26.9k
Omid Hamid United States 68 21.3k 1.3× 4.9k 0.5× 9.8k 2.0× 8.0k 2.0× 1.9k 0.7× 414 26.3k
Naiyer A. Rizvi United States 61 11.0k 0.7× 7.7k 0.9× 3.0k 0.6× 3.5k 0.9× 2.2k 0.8× 275 15.0k

Countries citing papers authored by Matthew D. Hellmann

Since Specialization
Citations

This map shows the geographic impact of Matthew D. Hellmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew D. Hellmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew D. Hellmann more than expected).

Fields of papers citing papers by Matthew D. Hellmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew D. Hellmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew D. Hellmann. The network helps show where Matthew D. Hellmann may publish in the future.

Co-authorship network of co-authors of Matthew D. Hellmann

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew D. Hellmann. A scholar is included among the top collaborators of Matthew D. Hellmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew D. Hellmann. Matthew D. Hellmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patel, Sandip Pravin, Teresa Alonso‐Gordoa, Susana Banerjee, et al.. (2024). Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(2). e007340–e007340. 25 indexed citations
2.
Rizvi, Naiyer A., Foluso O. Ademuyiwa, Z. Alexander Cao, et al.. (2023). Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. Journal for ImmunoTherapy of Cancer. 11(3). e005920–e005920. 24 indexed citations
3.
Schoenfeld, Adam J., Hira Rizvi, Danish Memon, et al.. (2022). Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. Clinical Cancer Research. 28(17). 3797–3803. 31 indexed citations
4.
Beattie, Jason, Hira Rizvi, Jia Luo, et al.. (2021). Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 9(2). e001884–e001884. 39 indexed citations
5.
Arbour, Kathryn C., Hira Rizvi, Andrew J. Plodkowski, et al.. (2021). Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 27(8). 2209–2215. 82 indexed citations
6.
Hellmann, Matthew D., Nicoletta Bivi, Boris Calderón, et al.. (2021). Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clinical Cancer Research. 27(10). 2773–2781. 84 indexed citations
7.
Luo, Jia, Jason Beattie, Hira Rizvi, et al.. (2021). Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. Journal of Thoracic Oncology. 16(10). 1759–1764. 74 indexed citations
8.
Zhang, Qu, Jia Luo, Song Wu, et al.. (2020). Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discovery. 10(12). 1842–1853. 221 indexed citations
9.
Alessi, Joao V., Biagio Ricciuti, Fangxin Hong, et al.. (2020). Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Journal for ImmunoTherapy of Cancer. 8(2). e001007–e001007. 40 indexed citations
10.
Litchfield, Kevin, James L. Reading, Emilia L. Lim, et al.. (2020). Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications. 11(1). 3800–3800. 68 indexed citations
11.
Hellmann, Matthew D., Pasi A. Jänne, Mateusz Opyrchal, et al.. (2020). Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy. Clinical Cancer Research. 27(4). 1019–1028. 83 indexed citations
12.
Hu‐Lieskovan, Siwen, Aaron Lisberg, Jesse M. Zaretsky, et al.. (2019). Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(16). 5061–5068. 56 indexed citations
13.
Offin, Michael, Hira Rizvi, Megan Tenet, et al.. (2018). Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers. Clinical Cancer Research. 25(3). 1063–1069. 230 indexed citations
14.
Yu, Helena A., Ken Suzawa, Emmet Jordan, et al.. (2018). Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical Cancer Research. 24(13). 3108–3118. 188 indexed citations
15.
Santini, Fernando C., Hira Rizvi, Andrew J. Plodkowski, et al.. (2018). Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunology Research. 6(9). 1093–1099. 263 indexed citations
16.
Hellmann, Matthew D., Jedd D. Wolchok, Monika Vyas, et al.. (2018). Acquired resistance to immunotherapy in MMR-D pancreatic cancer. Journal for ImmunoTherapy of Cancer. 6(1). 127–127. 27 indexed citations
17.
Arbour, Kathryn C., Hyunjae R. Kim, Jordan Dienstag, et al.. (2017). Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 24(2). 334–340. 317 indexed citations
18.
Nathanson, Tavi, Arun Ahuja, Alex Rubinsteyn, et al.. (2016). Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunology Research. 5(1). 84–91. 122 indexed citations
19.
Rekhtman, Natasha, M. Catherine Pietanza, Matthew D. Hellmann, et al.. (2016). Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets. Clinical Cancer Research. 22(14). 3618–3629. 325 indexed citations breakdown →
20.
Snyder, Alexandra, Vladimir Makarov, Matthew D. Hellmann, et al.. (2015). Genetics and immunology: reinvigorated. OncoImmunology. 4(10). e1029705–e1029705. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Reck Breakdown of academic impact, for papers by Benjamin Besse Breakdown of academic impact, for papers by Delvys Rodríguez‐Abreu Breakdown of academic impact, for papers by Christina B. Walter Breakdown of academic impact, for papers by Janis M. Taube Breakdown of academic impact, for papers by Florin‐Andrei Taran Breakdown of academic impact, for papers by David R. Spigel Breakdown of academic impact, for papers by Andreas D. Hartkopf Breakdown of academic impact, for papers by Omid Hamid Breakdown of academic impact, for papers by Naiyer A. Rizvi
Rankless by CCL
2026